Cyclacel Announces Commencement of Investigator-Initiated Phase 2 Trial

Loading...
Loading...
Cyclacel Pharmaceuticals, Inc.
CYC
, today announced that the first patient has been dosed in an investigator-initiated, translational, Phase 2 clinical study at The University of Texas MD Anderson Cancer Center.
Posted In: FDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...